Home sensor

MipSalus is committed to developing a home sensor allowing PKU patients to conveniently monitor the concentration of phenylalanine (Phe) in their blood. Daily Phe readings enable patients to swiftly adjust medication and food intake resulting in significant health benefits.

Under current practice, PKU patients are offered a few Phe tests per months – with a higher frequency for children, pregnant women and patients treated with KUVAN® – one of the products presently given to people affected by PKU. However, this is an expensive and time-consuming practice: PKU clinics draw blood from patients and forward samples to laboratories for analysis. Following the analysis, the laboratories return the test results to the PKU clinics who then inform the patients. MipSalus’ vision is to provide reliable Phe readings within minutes at home – to the benefits of patients, practitioners and ultimately the insurance companies and health authorities carrying the associated costs.

The home sensor project is based on the MipSalus team’s year-long experience with receptor technologies combined with MipSalus’ MIPs’ technology.

Whether a patient is given MipSalus’ forthcoming treatment or is treated with either Palynziq® or KUVAN® in combination with a low-protein diet and protein substitute tablets, the home sensor will be applicable to the treatment of PKU and other variants of Hyperphenylalaninemia – i.e. increased level of Phe in the blood.